Due to the intimate relationship between liver and kidney disease in hepatitis C virus (HCV) infection, treatment options for HCV-positive patients at any stage of chronic kidney disease (CKD) are essential. The availability of second-generation, direct-acting antiviral (DAA) combinations has allowed for the advent of interferon-sparing treatment regimens with shorter durations and minimal side effects. While many of the second-generation DAAs are principally metabolized by the hepatic system, dosing in severe renal impairment (creatinine clearance [CrCl] <30 mL/min) or dialysis has remained questionable due to limited experience. New evidence regarding the use of these agents in renal impairment continues to become available, as real-world experience with these treatment regimens is reported. Simeprevir, ledipasvir, paritaprevir, ombitasvir, dasabuvir, and daclatasvir have data to suggest safety in end-stage renal disease. While safety and efficacy with sofosbuvir remains uncertain, data are now available to support utilizing a dose adjustment when glomerular filtration rates are <30 mL/min. Upcoming regimens grazoprevir/elbasvir and daclatasvir/asunaprevir/beclavubir may provide further options for patients with advanced kidney disease, and ongoing studies will continue to provide guidance for this unique patient population. This article will review the currently available literature, including the newest emerging evidence, on the use of second-generation DAAs in CKD stages 3 to 5 and dialysis.
GhanyMGStraderDBThomasDL; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–1374.
2.
AlterMJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–2441.
3.
ShepardCWFinelliLAlterMJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–567.
4.
CacoubPRenouCRosenthalE. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe e’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore). 2000;79(1):47–56.
5.
LiWCLeeYYChenIC. Age and gender differences in the relationship between hepatitis C infection and all stages of Chronic kidney disease. J Viral Hepat. 2014;21(10):706–715. doi:10.1111/jvh.12199.
6.
de Oliveria AndradeLJD’OliveiraAMeloRC. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis. 2009;1(1):33–37.
7.
RaoAKLuckmanEWiseME. Outbreak of hepatitis C virus infections at an outpatient hemodialysis facility: the importance of infection control competencies. Nephrol Nurs J. 2013;40(2):101–110.
8.
PereiraBJLeveyAS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 1997;51(4):981–999.
9.
JadoulMCornuCvan Ypersele de StrihouC. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int. 1993;44(6):1322–1326.
10.
HuangCSHoMSYangCS. Hepatitis C markers in hemodialysis patients. J Clin Microbiol. 1993;31(7):1764–1769.
11.
ChenYCLinHYLiCY. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int. 2014;85(5):1200–1207.
12.
TsuiJIVittinghoffEShlipakMG. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167(12):1271–1276.
13.
LeeJJLinMYChangJS. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014;9(6):e100790.
14.
FabriziFTakkoucheBLunghiG. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14(10):697–703.
15.
BunchorntavakulCManeerattanapornMChavalitdhamrongD. Management of patients with hepatitis C infection and renal disease. World J Hepatol. 2015;7(2):213–225
16.
American Association for the Study of Liver Diseases/Infectious Disease Society of America/International Antiviral Society. Recommendations for testing, managing, and treating hepatitis C. Web site. http://hcvguidelines.org. Updated August 7, 2015. Accessed January 5, 2016.
17.
European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63(1):199–236. doi:10.1016/j.jhep.2015.03.025.
18.
Solvaldi [package insert]. Foster City, CA: Gilead Sciences, Inc; 2015.
19.
GaneEJRobsonRABonaciniM. Safety, antiviral efficacy, and pharmacokinetics of Sofosbuvir in patients with severe renal impairment. Paper presented at: 65th Annual Meeting of the American Association of Liver Diseases; November 7–11, 2014; Boston, MA.
20.
GaneEJRobsonRABonaciniM. Anti-Viral Efficacy and Pharmacokinetics (PK) of Sofosbuvir (SOF) in Patients with Severe Renal Impairment. J Hepatol. 2014;60(4):667a.
21.
SulkowskiMSNaggieSLalezariM; PHOTON-1 Investigators. Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection. JAMA. 2014;312(4):353–361.
22.
BhamidimarriKGutierrezJGrigorianA. Urgent treatment with Sofosbuvir based regimen for hepatitis C genotype 1 patients with severe renal insufficiency (GFR <30 mL/min). Paper presented at: 65th Annual Meeting of the American Association of Liver Diseases; November 7–11, 2014; Boston, MA.
23.
BhamidimarriKGutierrezJGrigorianA. Urgent treatment with Sofosbuvir based regimen for hepatitis C genotype 1 patients with severe renal insufficiency (GFR <30mL/min). Hepatology. 2014;60(4 suppl):688–689.
24.
CzulFBhamidimarriKPeytonA. Safety, efficacy and tolerability of half-dose Sofosbuvir dose Simeprevir in treatment of hepatitis C in patients with end stage renal disease. Paper presented at: 50th Annual Meeting of the European Association for the Study of the Liver; April 22–26, 2015; Vienna, Austria.
25.
SaxenaVKoraishyFMSiseM. Safety and efficacy of Sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-Target. Paper presented at: 50th Annual Meeting of the European Association for the Study of the Liver; April 22–26, 2015; Vienna, Austria.
GarimellaTWangRLuoWL. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther. 2015;20(5):535–543. doi:10.3851/IMP2941.
31.
Viekira Pak [package insert]. North Chicago, IL: AbbVie; 2015.
32.
PockrosPJReddyKRMantryPS. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study[Abstract L01.]. Paper presented at: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22–26, 2015: s257; Vienna, Austria.
33.
RothDNelsonDBruchfeldA. C-SURFER: Grazoprevir plus Elbasvir in Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Virus Genotype 1 Infection and Chronic Kidney Disease. Paper presented at: 2015 Annual Meeting of the European Association for the Study of the Liver; April 22–26, 2015: Vienna, Austria.
34.
AdamczykRSimsKHesneyM. The Effect of Renal Impairment on Multiple-Dose Pharmacokinetics of the Fixed-Dose Combination of Daclatasvir/Asunaprevir/Beclavubir. Paper presented at: 2015 Annual Meeting of the European Association for the Study of the Liver; April 22–26; 2015: Vienna, Austria.
